CompletedPhase 2NCT01466179
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Studying Precursor B-cell acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Amgen Research (Munich) GmbH
- Principal Investigator
- Nicola Gökbuget, MDKlinikum der Goethe Universität Frankfurt
- Intervention
- Blinatumomab(biological)
- Enrollment
- 225 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2011 – 2017
Study locations (30)
- City of Hope, Duarte, California, United States
- University of California Los Angeles, Los Angeles, California, United States
- Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
- Rush University Medical Center, Chicago, Illinois, United States
- University of Chicago, Chicago, Illinois, United States
- Dana Farber Institute, Boston, Massachusetts, United States
- Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Roswell Park Cancer Streets, Buffalo, New York, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- CHU d'Angers, Angers, France
- Hôpital de l'hôtel Dieu, Nantes, France
- Hôpital Saint Louis, Paris, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01466179 on ClinicalTrials.govOther trials for Precursor B-cell acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07441291CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCTPeking University People's Hospital
- RECRUITINGNANCT06689917JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ LeukemiaTongji Hospital
- RECRUITINGPHASE2NCT07244406Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALLHebei Senlang Biotechnology Inc., Ltd.
- RECRUITINGPHASE2NCT06554626Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALLFirst Affiliated Hospital of Zhejiang University
- RECRUITINGPHASE2NCT06111625Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALLSichuan University
- RECRUITINGPHASE1NCT04318678CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)St. Jude Children's Research Hospital
- RECRUITINGPHASE1, PHASE2NCT03765177CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic MalignanciesOttawa Hospital Research Institute
- ENROLLING BY INVITATIONNCT03226704Leukapheresis for CAR or Adoptive Cell Therapy ManufacturingNational Cancer Institute (NCI)
See all trials for Precursor B-cell acute lymphoblastic leukemia →